Aktueller Stand zur Sekundärprophylaxe des ischämischen Schlaganfalls

Zusammenfassung

Jährlich ereignen sich etwa 117 000 ischämische Schlaganfälle in Deutschland. Wird das Ereignis überlebt, beträgt die Rezidivrate bis zu 15% innerhalb des ersten Jahres. Oft ist der zerebrale Infarkt die erste klinische Organmanifestation einer ausgeprägten Atherosklerose mit erheblichem Risiko weiterer, extrazerebraler Komplikationen. In der vorliegenden Übersicht soll die aktuelle Studienlage zur Sekundärprophylaxe mit Thrombozytenfunktionshemmern, Antikoagulation, Interventionsmöglichkeiten bei Carotisstenose und ausgewählten Gefäßrisikofaktoren dargestellt werden.

Summary

There are about 117 000 strokes each year in Germany. The risk of recurrent stroke in survivors is estimated at up to 15%. The cerebral infarction frequently represents the initial clinical manifestation of a generalized atherosclerotic disease bearing an extensive risk of further extracerebral complications. This brief review mentions recent studies that impact clinical practice of secondary prevention including the choice of platelet inhibitors, anticoagulation, interventional therapy of carotid stenosis and management of certain modifiable risk factors.

Schlüsselwörter

Ischämischer Schlaganfall - Sekundärprophylaxe - Gefäßrisikofaktoren

Keywords

Ischemic stroke - secondary prevention - vascular risk factors

• Literatur

• 1 Prospective studies collaboration.. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995; 346: 1647-53.
• 2 CAPRIE Steering Committee.. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348 9038 1329-39.
• 3 PROGRESS Collaborative Group.. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358 9287 1033-41.
• 4 Antithrombotic Trialists’ Collaboration.. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Bmj 2002; 324 7329 71-86.
• 5 „AWMF Leitlinien für die Prävention, Erkennung, Diagnostik und Therapie der arteriellen Hypertonie 2003; www.uni-duesseldorf.de/WWWAWMF/ll/046–001.htm#4.1.
• 6 Amarenco P, Bogousslavsky J. et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355 (Suppl. 06) 549-59.
• 7 Atkins D. et al. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann Intern Med 1993; 119 (Suppl. 02) 136-45.
• 8 Balk E. et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003; 139 (Suppl. 08) 670-82.
• 9 Bhatt D. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354 (Suppl. 16) 1706-17.
• 10 Chimowitz M. et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352 (Suppl. 13) 1305-16.
• 11 Collins R. et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335 8693 827-38.
• 12 Diener C. [Secondary stroke prevention according to the PRoFESS Study. What are the sequelae for practical therapy?]. MMW Fortschr Med 2008; 150 (Suppl. 21) 7.
• 13 Diener HC. et al. Leitlinien der Deutschen Gesellschaft für Neurologie und der Deutschen Schlaganfallgesellschaft zur Primär- und Sekundärprävention des Schlaganfalls: Aktualisierung 2007. Akt Neurol 2007; 34: 8-12.
• 14 Diener HC. et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364 9431 331-7.
• 15 Diener HC. et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143 1–2 1-13.
• 16 Emberson J. et al. Lifestyle and cardiovascular disease in middle-aged British men: the effect of adjusting for within-person variation. Eur Heart J 2005; 26: 1774-1782.
• 17 Girona J. et al. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999; 83 (Suppl. 06) 846-51.
• 18 Goldstein L. et al. Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001; 32 (Suppl. 01) 280-99.
• 19 Gueyffier F. et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997; 28 (Suppl. 12) 2557-62.
• 20 Halkes P. et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367 9523 1665-73.
• 21 Hankey GJ. Smoking and risk of stroke. J Cardiovasc Risk 1999; 6 (Suppl. 04) 207-11.
• 22 Hankey G, Warlow C. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 1999; 354 9188 1457-63.
• 23 Hebert P. et al. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med 1995; 155 (Suppl. 01) 50-5.
• 24 Iribarren C. et al. Cohort study of exposure to environmental tobacco smoke and risk of first ischemic stroke and transient ischemic attack. Neuroepidemiologie 2004; 23 1–2 38-44.
• 25 Isaacsohn J. et al. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol 1994; 74 (Suppl. 07) 735-7.
• 26 Lee C. et al. Physical activity and stroke risk: a meta- analysis. Stroke 2003; 34 (Suppl. 10) 2475-81.
• 27 Lewington S. et al. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 9349 1903-13.
• 28 Leys D. et al. Stroke prevention: management of modifiable vascular risk factors. J Neurol 2002; 249 (Suppl. 05) 507-17.
• 29 Mas J. et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006; 355 (Suppl. 16) 1660-71.
• 30 Mukamal K. et al. Alcohol and risk for ischemic stroke in men: the role of drinking patterns and usual beverage. Ann Intern Med 2005; 142 (Suppl. 01) 11-9.
• 31 Naylor A. et al. Overview of the principal results and secondary analyses from the European and North American randomised trials of endarterectomy for symptomatic carotid stenosis. Eur J Vasc Endovasc Surg 2003; 26 (Suppl. 02) 115-29.
• 32 O’Driscoll G. et al. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95 (Suppl. 05) 1126-31.
• 33 O’Keefe J. et al. Alcohol and cardiovascular health: the razor-sharp double-edged sword. J Am Coll Cardiol 2007; 50 (Suppl. 11) 1009-14.
• 34 Reynolds K. et al. Alcohol consumption and risk of stroke: a meta-analysis. Jama 2003; 289 (Suppl. 05) 579-88.
• 35 Ringleb P. Two year results of the SPACE Study. Cerebrovasc Dis 2008; 25 (Suppl. 02) 1-204.
• 36 Ringleb P. et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 2006; 368 9543 1239-47.
• 37 Rothwell P. et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004; 363 9413 915-24.
• 38 Rothwell P. et al. Sex difference in the effect of time from symptoms to surgery on benefit from ca- rotid endarterectomy for transient ischemic attack and nondisabling stroke. Stroke 2004; 35 (Suppl. 12) 2855-61.
• 39 Sacco R. et al. Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. N Engl J Med 2008 259: online first.
• 40 Schrader J. et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36 (Suppl. 06) 1218-26.
• 41 Silagy C. et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; 3: CD000146.
• 42 Straznicky N. et al. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol 1995; 75 (Suppl. 08) 582-6.
• 43 Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362 9395 1527-35.
• 44 Verro P. et al. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke 2008; 39 (Suppl. 04) 1358-63.
• 45 Wassmann S. et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37 (Suppl. 06) 1450-7.
• 46 Wendel-Vos G. et al. Physical activity and stroke. A meta-analysis of observational data. Int J Epidemiol 2004; 33 (Suppl. 04) 787-98.
• 47 Weverling-Rijnsburger A. et al. Total cholesterol and risk of mortality in the oldest old. Lancet 1997; 350 9085 1119-23.
• 48 Yusuf S. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358 (Suppl. 15) 1547-59.
• 49 Zhang X. et al. Association of passive smoking by husbands with prevalence of stroke among Chinese women nonsmokers. Am J Epidemiol 2005; 161 (Suppl. 03) 213-8.